Declínio de longo prazo das ações da PFE devido a perdas de patentes

Pfizer's (PFE) long-term stock decline driven by patent losses and reduced growth prospects.

On April 9, 2026, Bank of America (BofA) lowered its price target on Pfizer Inc. (NYSE:PFE) to $26 from $27, maintaining a Neutral rating. This revision reflects BofA's Q1 preview across large-cap pharma, indicating reduced confidence in Pfizer's growth potential. Pfizer's stock has declined by 25% over the past five years, underperforming the S&P 500's 68% gain, as investors lose confidence in the company's ability to grow following patent losses on key drugs.

The pharmaceutical sector is affected, with investors re-evaluating their positions in companies reliant on patented drugs for growth. Pfizer's peers, such as Merck (MRK) and Bristol-Myers Squibb (BMY), may face similar scrutiny as their patents expire. The market is also watching for signs of innovation and pipeline strength, as these factors could help Pfizer and other pharma giants maintain growth.

What to watch next: Pfizer's Q1 earnings report on April 26, 2026, will provide insights into the company's current performance and guidance for the rest of the year. Additionally, regulatory decisions on Pfizer's pipeline drugs, particularly its breast cancer drug palbociclib, will be crucial in determining the company's growth trajectory. Lastly, investors will closely monitor Pfizer's share price to see if it can break its recent downtrend and challenge the $26 price target set by BofA.